BRIEF-Neurocrine Biosciences Provides Update On Phase 2 Data For Luvadaxistat In Adults With Cognitive Impairment Associated With Schizophrenia

Reuters09-13

Sept 12 (Reuters) - Neurocrine Biosciences Inc :

* NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON ERUDITE™ PHASE 2 DATA FOR LUVADAXISTAT IN ADULTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA

* NEUROCRINE BIOSCIENCES INC - LUVADAXISTAT DID NOT MEET PRIMARY ENDPOINT IN THIS STUDY

* NEUROCRINE BIOSCIENCES INC - PLAN TO HALT FURTHER DEVELOPMENT OF LUVADAXISTAT AT THIS TIME

* NEUROCRINE BIOSCIENCES- WILL FOCUS EFFORTS AND RESOURCES ON ADVANCEMENT INTO PHASE 3 CLINICAL DEVELOPMENT OF NBI-1117568 FOR SCHIZOPHRENIA

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467737202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-13 05:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467737202","market":"us","top_or_hot":-1,"title":"BRIEF-Neurocrine Biosciences Provides Update On Phase 2 Data For Luvadaxistat In Adults With Cognitive Impairment Associated With Schizophrenia","media":"Reuters","content":"<html><body><p>Sept 12 (Reuters) - Neurocrine Biosciences Inc   :</p><p>   * NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON ERUDITE™ PHASE 2 DATA FOR LUVADAXISTAT IN ADULTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA</p><p>   * NEUROCRINE BIOSCIENCES INC - LUVADAXISTAT DID NOT MEET PRIMARY ENDPOINT IN THIS STUDY</p><p>   * NEUROCRINE BIOSCIENCES INC - PLAN TO HALT FURTHER DEVELOPMENT OF LUVADAXISTAT AT THIS TIME</p><p>   * NEUROCRINE BIOSCIENCES- WILL FOCUS EFFORTS AND RESOURCES ON ADVANCEMENT INTO PHASE 3 CLINICAL DEVELOPMENT OF NBI-1117568 FOR SCHIZOPHRENIA</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neurocrine Biosciences Provides Update On Phase 2 Data For Luvadaxistat In Adults With Cognitive Impairment Associated With Schizophrenia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neurocrine Biosciences Provides Update On Phase 2 Data For Luvadaxistat In Adults With Cognitive Impairment Associated With Schizophrenia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-13 05:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 12 (Reuters) - Neurocrine Biosciences Inc   :   * NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON ERUDITE™ PHASE 2 DATA FOR LUVADAXISTAT IN ADULTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823416689.USD","symbol_name":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2467737202","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467737202","pubTimestamp":1726177987,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 12 (Reuters) - Neurocrine Biosciences Inc   :   * NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON ERUDITE PHASE 2 DATA FOR LUVADAXISTAT IN ADULTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","NBIX":"神经分泌生物科学","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"简介-Neurocrine Biosciences提供了Luvadaxistat治疗精神分裂症相关认知障碍成人的2期数据更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"Sept 12 (Reuters) - Neurocrine Biosciences Inc   :   * NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON ERUDITE™ PHASE 2 DATA FOR LUVADAXISTAT IN ADULTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA   * NEUROCRINE BIOSCIENCES INC - LUVADAXISTAT DID NOT MEET PRIMARY ENDPOINT IN THIS STUDY   * NEUROCRINE BIOSCIENCES INC - PLAN TO HALT FURTHER DEVELOPMENT OF LUVADAXISTAT AT THIS TIME   * NEUROCRINE BIOSCIENCES- WILL FOCUS EFFORTS AND RESOURCES ON ADVANCEMENT INTO PHASE 3 CLINICAL DEVELOPMENT OF NBI-1117568 FOR SCHIZOPHRENIASource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467737202"}